What is EVOTEC?
Evotec operates as a global platform company dedicated to the discovery and development of highly effective therapeutics. By integrating a proprietary, data-driven multimodality platform, the company bridges the gap between early-stage research and clinical-ready pharmaceutical products. Its business model is built upon a unique combination of innovative technologies, allowing it to address unmet medical needs through both internal R&D and strategic collaborations with global pharmaceutical partners. This dual-track strategy ensures that Evotec remains at the forefront of the biotechnology industry, consistently delivering first-in-class and best-in-class therapeutic solutions to patients worldwide.
How much funding has EVOTEC raised?
EVOTEC has raised a total of $772.9M across 8 funding rounds:
Stock Offering
$69.4M
Share Placement
$32.5M
Share Placement
$96.1M
Debt
$89.8M
Grant
$23.8M
Private Equity
$292.4M
Grant
$8.5M
Debt
$160.4M
Stock Issuance/Offering (1999): $69.4M, investors not publicly disclosed
Share Placement (2013): $32.5M led by Biotechnology Value Fund
Share Placement (2017): $96.1M supported by Novo A/S
Debt (2017): $89.8M featuring European Investment Bank
Grant (2019): $23.8M backed by Bill & Melinda Gates Foundation
Private Equity (2020): $292.4M with participation from Mubadala and Novo Holdings
Grant (2022): $8.5M led by German Federal Ministry of Education and Research
Debt (2023): $160.4M supported by European Investment Bank
Key Investors in EVOTEC
Novo A/S
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term value creation in the life sciences sector.
European Investment Bank
Established in 1958 and headquartered in Luxembourg, the European Investment Bank is the European Union's nonprofit long-term lending and finance institution.
Mubadala
Mubadala Investment Company is a sovereign investor managing a global portfolio to generate sustainable financial returns for Abu Dhabi, with a strong focus on healthcare and technology.
What's next for EVOTEC?
With the recent infusion of capital, Evotec is well-positioned to accelerate its R&D pipeline and further enhance its technological infrastructure. The company's strategic focus will likely remain on expanding its multimodality capabilities, which are essential for navigating the increasingly complex landscape of modern drug discovery. As the firm continues to scale, it will likely prioritize the optimization of its data-driven research engines to shorten development timelines and improve success rates for its proprietary therapeutic candidates. Furthermore, the continued support from institutional investors suggests a stable outlook for Evotec as it seeks to solidify its role as a critical partner in the global pharmaceutical ecosystem, driving long-term value through scientific innovation and operational excellence.
See full EVOTEC company page
